Recent Finacing
Recent Raise
Appili Therapeutics develops reformulated and novel anti‑infective therapeutics—GMP‑manufactured ATI‑1501 oral metronidazole suspension for anaerobic infections, ATI‑1503 negamycin‑analogue antibiotics, and an in‑licensed tularemia vaccine.
